Literature DB >> 8269361

Prevaccination bovine viral diarrhea virus titers and subsequent reproductive performance in dairy heifers.

P Michel1, M Thurmond, S Hietala.   

Abstract

The study was conducted to determine if there was a relationship between prevaccination bovine viral diarrhea virus (BVDV) titers in 14 month-old dairy heifers and time open during first lactation, length of the conception interval, fetal survival during the second pregnancy, and age at culling. Possible associations were analyzed using nonparametric survival methods and survival distributions were described using the product-limit (Kaplan Meier) methods. Regression analysis was used to estimate the correlation between pre- and postvaccination BVDV titers three years after vaccination. Evidence of exposure to BVDV prior to 14 months of age was demonstrated by serum-virus-neutralization titers greater than 1:4 for 97% and greater than or equal to 1:128 for 67% of the 72 heifers followed. No correlation was found for 38 pairs of prevaccination and postvaccination titers (p = 0.76). The risk of being culled was high for heifers (n = 41) with very low (1:2-1:8) or very high (> or = 1:256) titers, but low for heifers (n = 31) with moderate (1:16-1:128) prevaccination titers (p = 0.098). Risk of subsequent fetal loss was high for heifers (n = 30) with very low (1:2-1:16) or very high (> or = 1:256) prevaccination titers, compared to heifers (n = 24) with moderate (1:32-1:128) titers (p = 0.084). These findings suggest that prevaccination exposure to BVDV eliciting either a very weak or a very strong serological response may contribute to subsequent reproductive inefficiency and an increased risk of culling.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8269361      PMCID: PMC1263634     

Source DB:  PubMed          Journal:  Can J Vet Res        ISSN: 0830-9000            Impact factor:   1.310


  18 in total

1.  Considerations for use of descriptive epidemiology to investigate fetal loss in dairy cows.

Authors:  M C Thurmond; J P Picanso; C M Jameson
Journal:  J Am Vet Med Assoc       Date:  1990-11-15       Impact factor: 1.936

2.  STANDARDIZATION OF VIRUS-NEUTRALIZATION TEST FOR BOVINE VIRUS DIARRHEA.

Authors:  L COGGINS
Journal:  Am J Vet Res       Date:  1964-01       Impact factor: 1.156

Review 3.  Bovine viral diarrhea virus: a review.

Authors:  J C Baker
Journal:  J Am Vet Med Assoc       Date:  1987-06-01       Impact factor: 1.936

4.  Investigation of bovine viral diarrhea virus infections in a range beef cattle herd.

Authors:  C L Kelling; L C Stine; K K Rump; R E Parker; J E Kennedy; R T Stone; G S Ross
Journal:  J Am Vet Med Assoc       Date:  1990-09-01       Impact factor: 1.936

5.  Pathogenesis and epidemiology of bovine virus diarrhoea virus infection of cattle.

Authors:  J Brownlie; M C Clarke; C J Howard; D H Pocock
Journal:  Ann Rech Vet       Date:  1987

6.  Experimental production of fatal mucosal disease in cattle.

Authors:  J Brownlie; M C Clarke; C J Howard
Journal:  Vet Rec       Date:  1984-06-02       Impact factor: 2.695

7.  Association of bovine viral diarrhoea-mucosal disease virus with ovaritis in cattle.

Authors:  Y K Ssentongo; R H Johnson; J R Smith
Journal:  Aust Vet J       Date:  1980-06       Impact factor: 1.281

8.  Immune responsiveness in cattle fatally affected by bovine virus diarrhea-mucosal disease.

Authors:  F Steck; S Lazary; H Fey; A Wandeler; C Huggler; G Oppliger; H Baumberger; R Kaderli; J Martig
Journal:  Zentralbl Veterinarmed B       Date:  1980

9.  Studies on transplacental transmissibility of a Bovine Virus Diarrhoea (BVD) vaccine virus. I. Inoculation of pregnant cows 15 to 90 days before parturition (190th to 265th day of gestation).

Authors:  S Orban; B Liess; S M Hafez; H R Frey; H Blindow; B Sasse-Patzer
Journal:  Zentralbl Veterinarmed B       Date:  1983-09

10.  New concepts in the pathogenesis, diagnosis and control of diseases caused by the bovine viral diarrhea virus.

Authors:  O M Radostits; I R Littlejohns
Journal:  Can Vet J       Date:  1988-06       Impact factor: 1.008

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.